PL3007694T3 - Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego - Google Patents

Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego

Info

Publication number
PL3007694T3
PL3007694T3 PL14761286T PL14761286T PL3007694T3 PL 3007694 T3 PL3007694 T3 PL 3007694T3 PL 14761286 T PL14761286 T PL 14761286T PL 14761286 T PL14761286 T PL 14761286T PL 3007694 T3 PL3007694 T3 PL 3007694T3
Authority
PL
Poland
Prior art keywords
treatment
bladder cancer
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Application number
PL14761286T
Other languages
English (en)
Inventor
Chantal Alcouffe
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL3007694T3 publication Critical patent/PL3007694T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14761286T 2013-06-14 2014-06-13 Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego PL3007694T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1355578 2013-06-14
EP14761286.5A EP3007694B1 (en) 2013-06-14 2014-06-13 Pyrazolopyridine derivatives for use in the treatment of bladder cancer
PCT/EP2014/062456 WO2014198942A1 (en) 2013-06-14 2014-06-13 Pyrazolopyridine derivatives for use in the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
PL3007694T3 true PL3007694T3 (pl) 2018-12-31

Family

ID=48906407

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14761286T PL3007694T3 (pl) 2013-06-14 2014-06-13 Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego

Country Status (13)

Country Link
US (1) US9572799B2 (pl)
EP (1) EP3007694B1 (pl)
JP (1) JP2016521721A (pl)
KR (1) KR20160021134A (pl)
CN (1) CN105283184B (pl)
AU (1) AU2014280046B2 (pl)
CA (1) CA2915321A1 (pl)
EA (1) EA030558B1 (pl)
ES (1) ES2691923T3 (pl)
MX (1) MX2015017201A (pl)
PL (1) PL3007694T3 (pl)
TR (1) TR201815333T4 (pl)
WO (1) WO2014198942A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN108774224B (zh) * 2018-04-23 2020-10-30 浙江大学 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR20200111553A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 무선 통신 시스템에서 이중 접속을 위한 단말의 상향 채널 전송 방법 및 장치
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11647553B2 (en) 2019-08-08 2023-05-09 Samsung Electronics Co., Ltd. Method and apparatus for performing dual connectivity for UEs in wireless communication system
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5689069B2 (ja) * 2008-11-20 2015-03-25 ジェネンテック, インコーポレイテッド ピラゾロピリジンpi3k阻害剤化合物及び使用方法
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
MX2015017201A (es) 2016-04-06
US9572799B2 (en) 2017-02-21
US20160128989A1 (en) 2016-05-12
CN105283184A (zh) 2016-01-27
CN105283184B (zh) 2018-01-26
WO2014198942A1 (en) 2014-12-18
ES2691923T3 (es) 2018-11-29
EP3007694A1 (en) 2016-04-20
AU2014280046A1 (en) 2016-01-07
JP2016521721A (ja) 2016-07-25
EA030558B1 (ru) 2018-08-31
AU2014280046B2 (en) 2019-07-11
KR20160021134A (ko) 2016-02-24
EP3007694B1 (en) 2018-07-18
EA201690020A1 (ru) 2016-04-29
TR201815333T4 (tr) 2018-11-21
CA2915321A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
PL3007694T3 (pl) Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
IL246239A0 (en) Bicyclic heterocyclic compounds and their uses in healing
IL251630A0 (en) Combined therapy for use in cancer treatment
IL276733A (en) Use of Aribolin in cancer treatment
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
IL233493A (en) Imidazopyridine derivatives for cancer treatment
ZA201508530B (en) Pyrazolopyridine derivatives for use in the treatment of bladder cancer
EP3104863C0 (en) SALICYLATE FOR USE IN THE TREATMENT OF CANCER
GB201322755D0 (en) Bicyclic heterocycle compounds and their uses in therapy
GB201322958D0 (en) Uses of oligouronates in cancer treatment